Lung cancer in 2016: immunotherapy comes of age

Lancet Respir Med. 2016 Dec;4(12):947-949. doi: 10.1016/S2213-2600(16)30379-4. Epub 2016 Nov 22.

Authors

Paul L R Mitchell¹, Thomas John²

Affiliations

¹ Olivia Newton-John Cancer and Wellness Centre, Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia. Electronic address: paul.mitchell@austin.org.au.
² Olivia Newton-John Cancer and Wellness Centre, Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.

PMID: 27890503
DOI: 10.1016/S2213-2600(16)30379-4

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Humans
Immunotherapy
Ipilimumab / therapeutic use
Lung Neoplasms / drug therapy*
Nivolumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab
pembrolizumab